Brazil Healthcare Group Dasa Returns to Profit at R$9M in Q1

Diagnósticos da América S.A. — Dasa (B3: DASA3), Latin America’s largest diagnostic-medicine company and one of Brazil’s largest integrated healthcare groups — swung to a Q1 2026 net profit of R$9 million, reversing a R$111 million net loss in the same quarter a year earlier, according to adjusted figures released Tuesday May 12.

The comparable-basis figures exclude discontinued operations, divested assets, and the businesses contributed to the Rede Américas joint venture — the structure Dasa calls its “current scope.” Consolidated gross revenue grew 14 percent year-on-year to R$2.4 billion, with the gross margin expanding to 33.5 percent from 30.9 percent a year earlier, per the filing.

Adjusted EBITDA grew 28 percent to R$573 million in the quarter, with margin expanding 270 basis points to 25.8 percent. National diagnostics revenue rose 15 percent to nearly R$2.2 billion, driven by higher exam volumes and expansion of the premium, B2B corporate, and at-home care segments.

Net financial debt — after acquisitions payable and receivables anticipations — closed Q1 at R$5.6 billion, down from R$10.55 billion a year earlier, a 47 percent reduction. Leverage fell to 2.99 times net debt to EBITDA from 4.17 times at end-Q1 2025, signalling that the multi-year restructuring is now visible in the P&L.

Key Points

What Dasa Reported in Q1 2026

Dasa is Latin America’s largest diagnostic-medicine platform and one of Brazil’s largest integrated healthcare groups, operating more than 40 laboratory brands including Lavoisier, Delboni, Pasteur, Alta Diagnósticos and Salomão Zoppi. The company is controlled by the Bueno family and listed on B3 under the ticker DASA3.

Q1 2026 marks the first clean quarter under Dasa’s restructured operational footprint, which separates the company’s diagnostics business from the hospital operations that were merged with Amil’s into the Rede Américas joint venture in April 2025. The remaining hospital operations — Hospital São Domingos, Hospital da Bahia and AMO, all in the Northeast — sit outside the JV perimeter.

Net income reached R$9 million, reversing the R$111 million loss reported in Q1 2025. The figures are presented on a comparable basis that strips out discontinued operations, divested assets including the Argentine business and Mantris, and the hospital businesses now consolidated under Rede Américas — providing the cleanest view of the new operational structure.

Consolidated gross revenue grew 14 percent year-on-year to R$2.4 billion. The gross margin expanded 260 basis points to 33.5 percent from 30.9 percent a year earlier. Total operating expenses rose 6.3 percent to R$293 million — significantly below the revenue growth rate, providing operating leverage.

The diagnostics segment delivered the standout result. National diagnostics revenue grew 15 percent to nearly R$2.2 billion in the quarter. The company attributed the performance to higher exam volumes and expansion across three differentiated channels: the premium segment, the B2B corporate channel, and the at-home care service. The Hospitals and Oncology Northeast segment — the smaller of the two operational units — grew revenue 2 percent.

Consolidated adjusted EBITDA reached R$573 million, up 28 percent year-on-year, with margin expanding 270 basis points to 25.8 percent from 23.1 percent a year earlier. The result includes a non-recurring R$28 million charge from completion of the purchase-price-allocation (PPA) analysis tied to the Rede Américas transaction, which generated additional depreciation.

Cash generation improved materially. Operating cash generation of R$21 million in Q1 contrasted with R$43 million in cash consumption in the same period of 2025 — a R$64 million swing on a quarter typically heavy in working-capital absorption. Free cash flow was positive at R$5 million, the first quarterly positive print under the new structure.

The cash conversion cycle improved to 60 days from a higher reading in Q1 2025, reflecting better receivables management with health-plan operators. Working-capital management has been a structural challenge for the Brazilian healthcare sector, with insurer payment delays compressing cash flow across listed peers including Fleury and Rede D’Or.

The headline balance-sheet metric is the deleveraging. Net financial debt — after acquisitions payable and receivables anticipations — closed Q1 at R$5.6 billion, down from R$10.55 billion a year earlier. The 47 percent reduction reflects the proceeds from the Rede Américas transaction (which transferred approximately R$3.5 billion of debt to the JV), the sales of the Argentine operation and Mantris, and ongoing cash generation.

Leverage fell to 2.99 times net debt to EBITDA from 4.17 times at end-Q1 2025 — finally below the 2.99x covenant threshold that had pressured the company’s debt agreements for nearly two years. As the Rio Times noted at the time of the Q1 2025 release, the leverage ratio at that point stood at 5.07 times — meaning the deleveraging cycle has been more rapid than the original restructuring plan envisaged.

Why Dasa Q1 Matters

The R$9 million profit is small in absolute terms but enormous in narrative terms. Q1 2026 is the first clean quarter under the new operational structure — without the asset-sale charges, restructuring costs, or non-recurring items that have distorted reported earnings since 2023. The fact that the company generated a positive net result on this clean basis is the strongest evidence yet that the diagnostics-focused model can produce consistent earnings.

The restructuring path has been brutal. As the Rio Times reported on the Q4 2025 print, the year ended with a R$947.7 million net loss driven by a one-time write-down tied to a hospital divestiture, even as recurring EBITDA grew 21 percent. The Q1 2026 result removes the one-time charges and shows the underlying earnings power for the first time.

CEO Rafael Lucchesi’s strategic framing — “we conducted a relevant transformation at Dasa over the last twelve months, with organisational simplification, greater focus on the diagnostics core, and discipline in capital allocation” — is now backed by the operational data. Diagnostics revenue grew 15 percent; the segment now sits at the strategic centre of the business with R$2.2 billion in quarterly revenue.

The deleveraging from 4.17x to 2.99x is the structural validation of the Rede Américas transaction. By transferring hospital assets to the JV with Amil, Dasa offloaded approximately R$3.5 billion in debt and freed working capital from a hospital business that was structurally lower-margin than diagnostics. The trade-off was the loss of consolidated hospital revenue — but the resulting balance sheet is dramatically more resilient to the 15 percent Selic environment.

The Q1 print also showed the first signs that the company’s industrial-scale lab investment programme is bearing fruit. The premium and B2B corporate segments — where Dasa is investing heavily — are the highest-margin parts of the diagnostics franchise. As the Rio Times reported in February, Dasa launched its largest-ever capital investment programme to renovate 70 percent of its core lab capacity across 18 technical operating centres with equipment from Roche, Abbott and Beckman Coulter.

The peer comparison is instructive. Fleury (B3: FLRY3), Brazil’s premium diagnostics name, posted Q4 2025 net income of R$96 million on R$2.2 billion in revenue with a 22.1 percent EBITDA margin and leverage at 1.0x. Dasa’s restructured diagnostics franchise is now operating at a 25.8 percent EBITDA margin — above Fleury’s — though Fleury’s superior balance sheet and longer track record of consistent profitability still command a valuation premium.

Stock-market reaction in recent quarters has been pronounced. DASA3 rallied 60 percent in the 12 months leading into Q1 2026 as analysts began pricing in the restructuring success. The shares rebounded sharply on the Q3 2025 release in November, then consolidated through Q1 as investors waited to confirm whether the trajectory was sustainable on a clean-basis quarter.

Three structural questions remain. First, whether the Rede Américas JV — Brazil’s second-largest hospital network behind Rede D’Or — delivers positive equity contributions through equivalência patrimonial. The JV is operationally complex with 25 hospitals, 30 oncology centres and 23 clinics generating roughly R$10.6 billion in annual revenue. Integration risk between Dasa and Amil legacy assets remains real.

Second, working-capital sustainability. Brazilian health insurers have been pushing payment terms longer across the sector, and the 60-day cash conversion cycle Dasa now reports is still significantly longer than asset-light competitors operating with shorter receivables cycles. Any deterioration in operadora payment practices would lengthen the cycle and reduce free cash flow.

Third, sector consolidation. Brazil’s diagnostics market — approximately 17,000 registered laboratories serving 50 million private-plan beneficiaries plus the SUS public system, generating R$30+ billion in annual revenue — remains highly fragmented. Whether Dasa returns to acquisition mode after deleveraging completes, or whether a Rede D’Or-Fleury combination materialises, will define the competitive landscape over the next 24 months.

For investors, the Q1 print converts the restructuring narrative from “promise” to “evidence.” The R$9 million profit is the first clean-quarter positive net result since the crisis. If Q2 and Q3 deliver similar trajectories with continued EBITDA-margin expansion and stable Rede Américas equity contributions, the multi-year compression of DASA3 versus diagnostics peers should begin to reverse.

Dasa Q1 2026 Financial Snapshot

Balance Sheet and Segment Detail

What Happens Next for Dasa

Sustained profitability test: Q1 was the first clean-basis profit. Q2 and Q3 need to confirm that the diagnostics-focused model can produce consistent net income without recurring one-off charges. The R$28M PPA charge in Q1 was the last significant non-recurring item flagged by management.

Rede Américas equity contribution: The JV with Amil — Brazil’s second-largest hospital network — should start delivering positive equity contributions via equivalência patrimonial as integration synergies materialise. Watch this line in Q2 and Q3 prints; meaningful positive contributions would lift consolidated net income.

Lab overhaul completion: The Roche/Abbott/Beckman Coulter 18-NTO modernisation programme covering 70 percent of core lab capacity is in execution. Successful completion should lift the diagnostics margin further toward Fleury’s premium levels.

Working capital and operadora dynamics: The 60-day cash conversion cycle is an improvement but still longer than asset-light peers. Watch for whether Dasa can maintain or compress the cycle as health-plan payment terms tighten across the sector.

M&A optionality: With leverage now at 2.99x and the covenant breach risk effectively gone, Dasa has optionality to return to opportunistic acquisitions in Brazil’s fragmented diagnostics market. Watch for any deal announcements through the second half of 2026.

Frequently Asked Questions

How much did Dasa earn in Q1 2026?

Dasa reported net income of R$9 million in Q1 2026, reversing a R$111 million net loss in the same quarter a year earlier. Gross revenue grew 14 percent to R$2.4 billion, with gross margin expanding to 33.5 percent from 30.9 percent.

Adjusted EBITDA reached R$573 million, up 28 percent year-on-year, with margin at 25.8 percent. The figures are presented on a comparable basis that excludes discontinued operations, divested assets and the businesses contributed to the Rede Américas joint venture — providing the cleanest view of the restructured operational footprint.

What is the Rede Américas joint venture?

Rede Américas is a 50/50 joint venture between Dasa and Amil that consolidates the hospital and oncology operations of both companies. The structure was finalised in April 2025 and operates as Brazil’s second-largest hospital network behind Rede D’Or, with 25 hospitals, 30 oncology centres and 23 clinics generating roughly R$10.6 billion in annual revenue.

Dasa no longer consolidates the JV in its income statement; instead, the equity stake is accounted for via equivalência patrimonial (equity-method accounting). The transaction transferred approximately R$3.5 billion in debt from Dasa to the JV, which was the principal mechanism behind the deleveraging from 4.17x to 2.99x.

How much has Dasa deleveraged?

Net financial debt — after acquisitions payable and receivables anticipations — closed Q1 2026 at R$5.6 billion, down from R$10.55 billion a year earlier. The 47 percent reduction reflects the proceeds from the Rede Américas transaction, the sales of the Argentine operation and Mantris, and ongoing operating cash generation.

The leverage ratio (net debt to EBITDA) fell to 2.99 times from 4.17 times at end-Q1 2025. The trajectory is more rapid than the original restructuring plan envisaged. As of Q1 2025, the ratio stood at 5.07 times — meaning Dasa has reduced leverage by more than two turns in twelve months.

How does Dasa compare to Fleury?

Fleury (B3: FLRY3), Brazil’s premium diagnostics name, reported Q4 2025 net income of R$96 million on R$2.2 billion in revenue with a 22.1 percent EBITDA margin and leverage of 1.0 times net debt to EBITDA. Dasa’s restructured franchise now operates at a 25.8 percent EBITDA margin — above Fleury’s level.

However, Fleury’s superior balance sheet, longer track record of consistent profitability and tighter cash conversion cycle still command a valuation premium. Dasa’s discount to Fleury and to its own historical valuation reflects execution risk on the ongoing transformation. Consistent profitability across the next 2-3 quarters should compress that discount.

Updated: 2026-05-13T07:30:00-03:00 by Rio Times Editorial Desk

Dasa Q1 2026 | DASA3 earnings | Brazil healthcare | diagnostics | Rede Américas Amil JV | Rafael Lucchesi | Lavoisier Delboni Pasteur | The Rio Times